Sacubitril/Valsartan for heart failure with reduced ejection fraction
Part of Heart & circulation clinical trials.
This trial tests if a combination medication (sacubitril/valsartan) can improve the heart's ability to relax and fill properly in people with heart failure and a very weak heart pump (ejection fraction less than 35%). It's for patients who are already on standard heart failure medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with heart failure and your heart's pumping strength is less than 35% (called HFrEF).
- You are able to take the study medication (sacubitril/valsartan, also known as ARNI) and follow the instructions.
- You are already on standard heart failure treatments recommended by guidelines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called sacubitril/valsartan to see if it helps people who have both a prosthetic heart valve and heart failure with a weak heart pump. The goal is to improve heart function and symptoms.
This trial compares two blood-pressure and heart-failure medicines: sacubitril/valsartan versus ramipril, to see which improves heart pumping and heart structure over time. It’s aimed at people with ischemic (blocked-artery) heart failure with mid-range ejection fraction and ongoing symptoms.
This trial studies whether a heart medicine called ARNI (sacubitril-valsartan) is safe and works well for people who have a durable LVAD and moderate-to-severe heart pumping weakness. It may help improve symptoms and outcomes, while carefully checking side effects in this higher-risk group.
This study tests a medication (sacubitril/valsartan) to reduce scarring in the heart muscle for people with a type of heart failure where the heart pumps well but is stiff. The goal is to see if it can improve heart function and symptoms.
This trial tests a medicine called sacubitril-valsartan for people in rural Tanzania with heart failure and reduced pumping strength. It aims to see if switching to this drug can improve symptoms and outcomes.
This trial studies whether sacubitril-valsartan works better than enalapril to improve heart healing after a specific type of heart attack. It aims to see if the heart’s shape and pumping recover more effectively.
Hear when a new Left Ventricular Diastolic Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.